The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

See a complete list of all our guidance and quality standards currently open for consultation ...

Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England. People ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of ...